Lisata Therapeutics (NASDAQ:LSTA) Announces Quarterly Earnings Results

Lisata Therapeutics (NASDAQ:LSTA – Get Free Report) released its quarterly earnings results on Friday. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.39, FiscalAI reports.

Lisata Therapeutics Stock Down 5.5%

Shares of LSTA stock traded down $0.07 during trading on Friday, hitting $1.21. The company had a trading volume of 104,779 shares, compared to its average volume of 184,319. The stock’s 50-day moving average is $1.29 and its two-hundred day moving average is $2.89. The stock has a market capitalization of $13.07 million, a price-to-earnings ratio of -0.74 and a beta of 1.04. Lisata Therapeutics has a 52 week low of $0.96 and a 52 week high of $5.07.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Lisata Therapeutics in a research report on Wednesday. Two investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce”.

Read Our Latest Analysis on LSTA

About Lisata Therapeutics

(Get Free Report)

Lisata Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for solid tumors. The company’s approach is designed to improve the delivery and effectiveness of cancer treatments by targeting the tumor microenvironment, which can limit the penetration of medicines into tumors. Lisata’s lead investigational product is certepetide, formerly known as CEND-1. Certepetide is a tumor-penetrating peptide intended to selectively home to tumor tissue and temporarily modify the tumor microenvironment, potentially helping co-administered anticancer therapies reach cancer cells more effectively.

Read More

Earnings History for Lisata Therapeutics (NASDAQ:LSTA)

Receive News & Ratings for Lisata Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lisata Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.